ArticleDigestive diseases and sciences2011
Carbon monoxide liberated from carbon monoxide-releasing molecule exerts an anti-inflammatory effect on dextran sulfate sodium-induced colitis in mice.
Article in Digestive diseases and sciences, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 77 citations in OpenAlex.
- A preclinical investigation into the potential associations of geraniin with ulcerative colitis alleviation through integrated multi-omics andFrontiers in medicine · 2026Article
- In vivo systematic analysis of microbiota-prebiotic crosstalk reveals a synbiotic that effectively ameliorates DSS-induced colitis in mice.Gut microbes · 2025Article
- Inhibition ofeLife · 2024Article
- Inhibition ofbioRxiv : the preprint server for biology · 2024Article
- Article
- Protective effect ofFrontiers in microbiology · 2022Article
- RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis.Autophagy · 2021Article
- The effect of carbon monoxide releasing molecule-2 (CORM-2) on healing of ischemic colon anastomosis in ratsTurkish journal of medical sciences · 2021Article
- Nature's marvels endowed in gaseous molecules I: Carbon monoxide and its physiological and therapeutic roles.Acta pharmaceutica Sinica. B · 2021Review
- Organic carbon monoxide prodrug, BW-CO-111, in protection against chemically-induced gastric mucosal damage.Acta pharmaceutica Sinica. B · 2021Article
- Construction of a "Bacteria-Metabolites" Co-Expression Network to Clarify the Anti-Ulcerative Colitis Effect of Flavonoids ofFrontiers in pharmacology · 2021Article
- Colon tissue-accumulating mesoporous carbon nanoparticles loaded withTheranostics · 2021Article
- CORM-2-entrapped ultradeformable liposomes ameliorate acute skin inflammation in an ear edema modelActa pharmaceutica Sinica. B · 2020Article
- Carbon monoxide: An emerging therapy for acute kidney injury.Medicinal research reviews · 2020Review
- Article
- Protective role of heme oxygenase-1 in fatty liver ischemia-reperfusion injury.Medical molecular morphology · 2019Review
- Effect ofEvidence-based complementary and alternative medicine : eCAM · 2019Article
- Heme oxygenase-1 prevents murine intestinal inflammation.Journal of clinical biochemistry and nutrition · 2018Article
- Research Progress in Understanding the Relationship Between Heme Oxygenase-1 and Intracerebral Hemorrhage.Frontiers in neurology · 2018Review
- Gaseous Mediators in Gastrointestinal Mucosal Defense and Injury.Digestive diseases and sciences · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndogenous carbon monoxide (CO) is one of the three products of heme degradation by heme oxygenase-1 (HO-1) and exerts novel anti-inflammatory and anti-apoptotic effects as a gaseous second messenger. The purpose of this investigation was to determine whether exogenous CO could modulate intestinal inflammation.
methodsAcute colitis was induced with 2% DSS in male C57BL/6 mice. CO-releasing molecule-2 (CORM-2; tricarbonyldichlororuthenium(II) dimer) was intraperitoneally administered twice daily and the disease activity index (DAI) was determined. We measured tissue-associated myeloperoxidase (MPO) activity as an index of neutrophil infiltration, and the production of keratinocyte chemoattractant (KC) and tumor necrosis factor-α (TNF-α) protein in the intestinal mucosa. In an in-vitro study, young adult mouse colonic epithelial (YAMC) cells were incubated with TNF-α, and KC mRNA/protein expression and nuclear translocation of nuclear factor-kappa B (NF-κB) were measured with or without CORM-2 treatment.
resultsAfter DSS administration, DAI score increased in a time-dependent manner, and this increase was ameliorated by CORM-2 treatment. Increases in MPO activity and in the production of KC and TNF-α after DSS administration were significantly inhibited by CORM-2. TNF-α-induced KC production in YAMC cells was also inhibited by CORM-2 treatment. Further, nuclear translocation of NF-κB in YAMC cells was inhibited by CORM-2.
conclusionCORM-liberated CO significantly inhibited inflammatory response in murine colitis by inhibition of cytokine production in the colonic epithelium. These results suggest that CO could become a new therapeutic molecule for inflammatory bowel disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.